Skip to content

Taysha Gene Therapies, Inc.

TSHA· NasdaqCore metricsCIK 1806310

Biological products, except diagnostic substances175 peers

Last sale
Oct 23, 2026 · -1.12%
Market cap
$1.29B
325.88M shares
Filings
404
$0.00
Q3 2026+17.3% FY25 yoy
-$39.13M
Q3 2026N/M FY25 yoy
-$41.87M
Q3 2026N/M FY25 yoy
-$114.68M
Q3 2026derivedN/M FY25 yoy
-$0.10
Q3 2026N/M FY25 yoy
$422.83M
Q3 2026+130.0% FY25 yoy
$1.29B
—
235.6×
3.6×
-10.96%
—

Twelve months to Sep 30, 2026 · derived

Price

$3.9719.66%$0.97past year
Oct 23, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$9.77MFY 2025
$15.45M0FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$9,773,000reported
FY 20242024-12-31$8,333,000reported
FY 20232023-12-31$15,451,000reported
FY 20222022-12-31$2,502,000reported

Biological products, except diagnostic substances

Taysha Gene Therapies, Inc. is the 63rd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Taysha Gene Therapies, Inc. · CIK 1806310 · Engraved from SEC EDGAR